SARS-CoV-2 RT-PCR testing
SARS-CoV-2 (previously 2019-nCoV) is a member of the coronavirus family and the causative agent of coronavirus disease 2019 (COVID-19). Since the first cases of a severe respiratory disease were reported from Wuhan, China, in December 2019, infections have spread rapidly around the world, and the number of confirmed COVID-19 cases worldwide has now reached 225,82 Mio (15.09.2021), Johns Hopkins University, https://coronavirus.jhu.edu/map.html).
Considering the rapid escalation and propagation of the COVID-19 worldwide, testing is indispensable and required in large quantities all over the world.
Current altona SARS-CoV-2 test kits reactivity analyses in response to mutations
Reactivity of molecular diagnostic tests is determined by the sequences of the oligonucleotides contained in the reaction mix. RNA viruses in particular have an inherently high mutation rate leading to changes in the genome sequence during every replication event. SARS-CoV-2 is no exception. We at altona Diagnostics are well aware of the importance to constantly monitor the emerging and circulating sequences and we update the reactivity analysis of our assays on a regular basis. Mutations in the viral genome occur in every gene and untranslated region and are not limited to the S gene. Our S gene assay is located in a conserved region coding for the membrane fusion subunit (domain 2) of the spike protein. Until now, we have not found any mutations that would cause our S gene assay to fail.
RealStar® SARS-CoV-2 Virus RT-PCR Kit 1.0
The CE-IVD certified RealStar® SARS-CoV-2 Virus RT-PCR Kit 1.0 consists of Master Reagents, Positive Control and an Internal Control and delivers highly reliable results. It is designed as a dual target assay and allows rapid screening of all lineage B-betacoronaviruses and confirms the presence of SARS-CoV-2 specific RNA in only one reaction.
AltoStar® SARS-CoV-2 RT-PCR Kit 1.5
The CE-IVD marked AltoStar® SARS-CoV-2 RT-PCR Kit 1.5 extends the altona Diagnostics test kit portfolio for the detection of SARS-CoV-2 specific RNA. The assay is intended for use with the automated AltoStar® Molecular Diagnostic Workflow and complements the existing RealStar® SARS-CoV-2 detection kits for use with open platforms. In addition, altona provides a corresponding kit for influenza virus detection, the AltoStar® Influenza Screen & Type RT-PCR Kit 1.5.
New altona product line FlexStar® starts with parallel-detection SARS-CoV-2/influenza PCR kits
FlexStar® is the quick and flexible real-time PCR product line allowing syndrome-based testing of different pathogens. Responding to the current situation, altona starts with dual target detection kits for SARS-CoV-2 (E gene and S gene) and Influenza A and B.
- Optimized PCR design for fast cycling – 96 results per real-time PCR cycler in just 1 hour
- Dual target detection of SARS-CoV-2 – safe detection of all described virus variants
- High performance – high sensitivity
- Different assay configurations available – differential detection of SARS E gene and S gene plus influenza or influenza A&B differentiation plus SARS (E gene and S gene)
RealStar® Respiratory Kit Bundle
Distinguishing respiratory tract infections is vital for patient management and epidemiological control. altona Diagnostics offers CE-marked RealStar® PCR kits for detecting three pathogens, namely SARS-CoV-2, Influenza viruses and RSV.
Each kit bundle can be ordered with a total of 384 reactions per included assay and will be available at special prices in your country. For an individual offer please contact your local sales representative.